Literature DB >> 2584938

The immunogenicity of chimeric antibodies.

M Brüggemann1, G Winter, H Waldmann, M S Neuberger.   

Abstract

Mice were immunized with model xenogeneic (both the VH frameworks and the CH domains of human origin), chimeric (just VH frameworks human), or self antibodies, and the antiantibody responses were dissected. Only the self antibody did not elicit a response. A strong response was elicited by the most xenogeneic antibody with approximately 90% against the C and approximately 10% against the V. The anti-V response was not attenuated in the chimeric antibody, demonstrating that foreign VH frameworks can be sufficient to lead to a strong antiantibody response. The magnitude of this xenogeneic anti-VH response was similar to that of the allotypic response elicited by immunizing mice of the Igha allotype with an Ighb antibody. Thus, although chimerization can diminish antiantibody responses, attention should be paid both to V region immunogenicity and to polymorphism.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2584938      PMCID: PMC2189553          DOI: 10.1084/jem.170.6.2153

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  7 in total

1.  Replacing the complementarity-determining regions in a human antibody with those from a mouse.

Authors:  P T Jones; P H Dear; J Foote; M S Neuberger; G Winter
Journal:  Nature       Date:  1986 May 29-Jun 4       Impact factor: 49.962

Review 2.  Immunoglobulin G: functional sites.

Authors:  D R Burton
Journal:  Mol Immunol       Date:  1985-03       Impact factor: 4.407

3.  Mouse immunoglobulin allotypes: post-duplication divergence of gamma 2a and gamma 2b chain genes.

Authors:  R Ollo; F Rougeon
Journal:  Nature       Date:  1982-04-22       Impact factor: 49.962

4.  A hapten-specific chimaeric IgE antibody with human physiological effector function.

Authors:  M S Neuberger; G T Williams; E B Mitchell; S S Jouhal; J G Flanagan; T H Rabbitts
Journal:  Nature       Date:  1985 Mar 21-27       Impact factor: 49.962

5.  Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.

Authors:  M Brüggemann; G T Williams; C I Bindon; M R Clark; M R Walker; R Jefferis; H Waldmann; M S Neuberger
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

6.  Association of H-2 types with genetic control of immune reponsiveness to IgG (gamma2a) allotypes in the mouse.

Authors:  R Lieberman; W Humphrey
Journal:  J Exp Med       Date:  1972-11-01       Impact factor: 14.307

7.  Tolerance to rat monoclonal antibodies. Implications for serotherapy.

Authors:  R J Benjamin; S P Cobbold; M R Clark; H Waldmann
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307

  7 in total
  31 in total

1.  Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer.

Authors:  Christine Mall; Gail D Sckisel; David A Proia; Annie Mirsoian; Steven K Grossenbacher; Chien-Chun Steven Pai; Mingyi Chen; Arta M Monjazeb; Karen Kelly; Bruce R Blazar; William J Murphy
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

2.  Obtaining a functional recombinant anti-rhesus (D) antibody using the baculovirus-insect cell expression system.

Authors:  L Edelman; C Margaritte; H Chaabihi; E Monchâtre; D Blanchard; A Cardona; F Morin; G Dumas; S Petres; M Kaczorek
Journal:  Immunology       Date:  1997-05       Impact factor: 7.397

3.  The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics.

Authors:  J Corne; R Djukanovic; L Thomas; J Warner; L Botta; B Grandordy; D Gygax; C Heusser; F Patalano; W Richardson; E Kilchherr; T Staehelin; F Davis; W Gordon; L Sun; R Liou; G Wang; T W Chang; S Holgate
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

4.  A humanized anti-DLL4 antibody promotes dysfunctional angiogenesis and inhibits breast tumor growth.

Authors:  Xuelian Jia; Wenyi Wang; Zhuobin Xu; Shijing Wang; Tong Wang; Min Wang; Min Wu
Journal:  Sci Rep       Date:  2016-06-15       Impact factor: 4.379

Review 5.  Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.

Authors:  Zulmarie Perez Horta; Jacob L Goldberg; Paul M Sondel
Journal:  Immunotherapy       Date:  2016-09       Impact factor: 4.196

6.  Humanized antibodies for antiviral therapy.

Authors:  M S Co; M Deschamps; R J Whitley; C Queen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

7.  Antibodies generated from human immunoglobulin miniloci in transgenic mice.

Authors:  S D Wagner; G T Williams; T Larson; M S Neuberger; D Kitamura; K Rajewsky; J Xian; M Brüggemann
Journal:  Nucleic Acids Res       Date:  1994-04-25       Impact factor: 16.971

Review 8.  Antibody engineering to develop new antirheumatic therapies.

Authors:  John D Isaacs
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

9.  Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses.

Authors:  S Stephens; S Emtage; O Vetterlein; L Chaplin; C Bebbington; A Nesbitt; M Sopwith; D Athwal; C Novak; M Bodmer
Journal:  Immunology       Date:  1995-08       Impact factor: 7.397

10.  Combinatorial autoantibodies to dihydrolipoamide acetyltransferase, the major autoantigen of primary biliary cirrhosis.

Authors:  S Cha; P S Leung; M E Gershwin; M P Fletcher; A A Ansari; R L Coppel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.